Extract
“GINA 2019: a fundamental change in asthma management.” This is how Reddel et al. [1] headline their editorial on the report in question. Reddel et al. [1] express a fundamental concept: “GINA no longer recommends treatment of asthma in adolescents and adults with SABA alone. Instead, to reduce their risk of serious exacerbations, all adults and adolescents with asthma should receive either symptom-driven (in mild asthma) or daily inhaled corticosteroid (ICS)-containing treatment.” We have some doubts about the full suitability of this change.
Abstract
There is not yet sufficient evidence to transfer the use of as-needed low dose ICS–formoterol, as GINA has recommended since 2019, instead of as-needed SABA to patients affected by step 1 asthma https://bit.ly/2G1IieN
Footnotes
Conflict of interest: S. Ferretti has nothing to disclose.
Conflict of interest: M. Gelsomino has nothing to disclose.
Conflict of interest: S. Miceli Sopo has nothing to disclose.
- Received August 31, 2020.
- Accepted September 23, 2020.
- ©ERS 2021.